Your browser doesn't support javascript.
loading
ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers?
Nagasaka, Misako; Ly, Catherine T; Ou, Sai-Hong Ignatius.
Affiliation
  • Nagasaka M; University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address: nagasakm@hs.uci.edu.
  • Ly CT; University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.
  • Ou SI; University of California Irvine School of Medicine, Department of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address: siou@hs.uci.edu.
Med ; 5(7): 649-651, 2024 Jul 12.
Article in En | MEDLINE | ID: mdl-39002534
ABSTRACT
The ALINA trial1 demonstrated that 2 years of adjuvant alectinib achieved statistically significantly improved 2-year overall and central nervous system (CNS) disease-free survival over platinum-doublet chemotherapy in resected early-stage (IB ≥ 4 cm to IIIA) ALK+ non-small cell lung cancer (NSCLC). Identifying early-stage ALK+ NSCLC patients (60% were never-smokers in the ALINA trial) may require low-dose computed tomography (LDCT) lung cancer screening in never-smokers.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tomography, X-Ray Computed / Carcinoma, Non-Small-Cell Lung / Early Detection of Cancer / Lung Neoplasms Limits: Humans Language: En Journal: Med Year: 2024 Document type: Article Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tomography, X-Ray Computed / Carcinoma, Non-Small-Cell Lung / Early Detection of Cancer / Lung Neoplasms Limits: Humans Language: En Journal: Med Year: 2024 Document type: Article Country of publication: Estados Unidos